Physician profile
David M Pegouske
NPI 1932201183
$19,286.47
in general payments reported to CMS, 2019-2025
41 companies · $2,000 in 2025
The $2,000 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,310 · 2020: $1,427 · 2021: $2,004 · 2022: $2,955 · 2023: $2,238 · 2024: $5,351 · 2025: $2,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,349 · Consulting Fee: $2,800 · Education: $301 · Travel and Lodging: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,348.73 |
| Consulting Fee | $2,800.00 |
| Education | $300.90 |
| Travel and Lodging | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $5,028.89 | 2019-2025 | Ilumya, Winlevi |
| Abbvie INC. | $2,348.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,567.02 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,306.76 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,151.38 | 2019-2025 | |
| Genzyme Corporation | $990.79 | 2019-2025 | |
| Lilly USA, LLC | $886.32 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Pfizer INC. | $869.96 | 2019-2024 | |
| Ucb, INC. | $808.69 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $567.71 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $542.96 | 2020-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $378.52 | 2022-2024 | Sotyktu |
| Hill Dermaceuticals, INC. | $332.14 | 2023 | Tolak |
| Almirall LLC | $322.21 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $311.53 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $233.85 | 2023-2024 | Vtama |
| Incyte Corporation | $214.07 | 2021-2025 | Opzelura |
| Genentech USA, INC. | $213.10 | 2019-2024 | Erivedge |
| Janssen Scientific Affairs, LLC | $157.43 | 2019-2022 | |
| Galderma Laboratories, L.P. | $111.07 | 2019-2025 | Nemluvio |
| Celgene Corporation | $107.95 | 2019 | |
| Epi Health, LLC | $88.34 | 2019-2021 | |
| Dusa Pharmaceuticals, INC. | $83.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.98 | 2023-2025 | Cyltezo, Spevigo |
| Dermira, INC. | $64.39 | 2020-2021 | |
| Biofrontera INC. | $62.24 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $58.12 | 2024-2025 | Ycanth |
| Kerecis Limited | $49.80 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Convatec INC. | $49.68 | 2024-2025 | |
| Allergan, INC. | $49.54 | 2019-2020 | |
| Tactile Systems Technology INC | $33.72 | 2024 | Entre Plus, Flexitouch Plus |
| Journey Medical Corporation | $32.80 | 2022 | |
| Sandoz INC. | $29.31 | 2020 | |
| Merck Sharp & Dohme LLC | $29.05 | 2019 | |
| Cipher Pharmaceuticals US LLC | $23.46 | 2025 | Natroba, Spinosad |
| Arcutis Biotherapeutics, INC. | $22.02 | 2024 | Zoryve |
| Organogenesis INC. | $21.24 | 2025 | Affinity |
| Vyne Pharmaceuticals INC. | $21.00 | 2021 | |
| Organon LLC | $20.13 | 2023 | Hadlima |
| Prugen, INC. Pharmaceuticals | $15.97 | 2019 | |
| Cashflow Solutions, LLC | $13.01 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pegouske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.